Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines

British Journal of Anaesthesia

Volumn 106, Issue 1, 2011, Pages 13-22

  Goodnough, L T ^a   Maniatis, A ^b   Earnshaw, P ^c   Benoni, G ^d   Beris, P ^e   Bisbe, E ^f   Fergusson, D A ^g   Gombotz, H ^h   Habler, O ⁱ   Monk, T G ^j   Ozier, Y ^k   Slappendel, R ^l   Szpalski, M ^m  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY DUNANT HOSPITAL   (Greece)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f HOSPITAL DE L ESPERANÇA   (Spain)

^g UNIVERSITY OF OTTAWA   (Canada)

^h KEPLER UNIVERSITY HOSPITAL   (Austria)

ⁱ KRANKENHAUS NORDWEST   (Germany)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k Paris Descartes University ^*  (France)

^l Perioperative Medicine Consultancy   (Netherlands)

^m FREE UNIVERSITY OF BRUSSELS   (Belgium)

more..

Author keywords

anaemia; blood transfusion; orthopaedic surgery; preoperative assessment; preoperative preparation

Indexed keywords

ALGORITHM; ANEMIA; ELECTIVE SURGERY; HUMAN; METHODOLOGY; ORTHOPEDIC SURGERY; PRACTICE GUIDELINE; PREOPERATIVE CARE; REVIEW;

ALGORITHMS; ANEMIA; HUMANS; ORTHOPEDIC PROCEDURES; PREOPERATIVE CARE; SURGICAL PROCEDURES, ELECTIVE;

EID: 79551552147     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeq361     Document Type: Review

References (110)

1. Nutritional anaemias, Report of a WHO scientific group, 1968, World Health Organization, Geneva World Health Organization Technical Report Series No. 405.
2. Guralnik, JM, Eisenstaedt, RS, Ferrucci, L, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 104 (2004), 2263–2268 doi:10.1182/blood-2004-05-1812.
3. Goodnough, LT, Nissenson, AR, Dubois, RW, Anemia: not just an innocent bystander?. Arch Intern Med 163 (2003), 1400–1404 doi:10.1001/archinte.163.12.1400.
4. Bierbaum, BE, Callaghan, JJ, Galante, JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 81 (1999), 2–10.
5. Guyatt, GH, Patterson, C, Ali, M, et al. Diagnosis of iron-deficiency anemia in the elderly. Am J Med 88 (1990), 205–209 doi:10.1016/0002-9343(90)90143-2.
6. Wilson, A, Yu, HT, Goodnough, LT, Nissenson, AR, Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 116:Suppl. 7A (2004), 50–57 doi:10.1016/j.amjmed.2003.12.012.
7. Bisbe, E, Castillo, J, Sáez, M, et al. Prevalence of preoperative anemia and hematinic deficiencies in patients scheduled for elective major orthopedic surgery. Transfus Alternat Transfus Med 10 (2008), 166–173 doi:10.1111/j.1778-428X.2008.00118.x.
8. Saleh, E, McClelland, DB, Hay, A, et al. Prevalence of anaemia before major joint arthroplasty and the potential impact of preoperative investigation and correction on perioperative blood transfusions. Br J Anaesth 99 (2007), 801–808 doi:10.1093/bja/aem299.
9. Weiss, G, Goodnough, LT, Anemia of chronic disease. N Engl J Med 352 (2005), 1011–1023 doi:10.1056/NEJMra041809.
10. Carson, JL, Duff, A, Poses, RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 348 (1996), 1055–1060 doi:10.1016/S0140-6736(96)04330-9.
11. Gruson, KI, Aharonoff, GB, Egol, KA, et al. The relationship between admission hemoglobin level and outcome after hip fracture. J Orthop Trauma 16 (2002), 39–44 doi:10.1097/00005131-200201000-00009.
12. Beattie, WS, Karkouti, K, Wijeysundera, DN, Tait, G, Risk associated with preoperative anemia in noncardiac surgery: a single-center cohort study. Anesthesiology 110 (2009), 574–581 doi:10.1097/ALN.0b013e31819878d3.
13. Wu, WC, Schifftner, TL, Henderson, WG, et al. Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. J Am Med Assoc 297 (2007), 2481–2488 doi:10.1001/jama.297.22.2481.
14. Khanna, MP, Hebert, PC, Fergusson, DA, Review of the clinical practice literature on patient characteristics associated with perioperative allogeneic red blood cell transfusion. Transfus Med Rev 17 (2003), 110–119 doi:10.1053/tmrv.2003.50008.
15. Shander, A, Knight, K, Thurer, R, et al. Prevalence and outcomes of anemia in surgery: a systematic review of the literature. Am J Med 116:Suppl. 7A (2004), 58–69S doi:10.1016/j.amjmed.2003.12.013.
16. Gruson, KI, Accousti, KJ, Parsons, BO, et al. Transfusion after shoulder arthroplasty: an analysis of rates and risk factors. J Shoulder Elbow Surg 18 (2009), 225–230 doi:10.1016/j.jse.2008.08.005.
17. Halm, EA, Wang, JJ, Boockvar, K, et al. The effect of perioperative anemia on clinical and functional outcomes in patients with hip fracture. J Orthop Trauma 18 (2004), 369–374 doi:10.1097/00005131-200407000-00007.
18. Lawrence, VA, Silverstein, JH, Cornell, JE, et al. Higher Hb level is associated with better early functional recovery after hip fracture repair. Transfusion 43 (2003), 1717–1722 doi:10.1046/j.0041-1132.2003.00581.x.
19. Conlon, NP, Bale, EP, Herbison, GP, McCarroll, M, Postoperative anemia and quality of life after primary hip arthroplasty in patients over 65 years old. Anesth Analg 106 (2008), 1056–1061 doi:10.1213/ane.0b013e318164f114.
20. Carson, JL, Noveck, H, Berlin, JA, Gould, SA, Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 42 (2002), 812–818 doi:10.1046/j.1537-2995.2002.00123.x.
21. Myers, E, O'Grady, P, Dolan, AM, The influence of preclinical anaemia on outcome following total hip replacement. Arch Orthop Trauma Surg 124 (2004), 699–701 doi:10.1007/s00402-004-0754-6.
22. Weiskopf, RB, Viele, MK, Feiner, J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. J Am Med Assoc 279 (1998), 217–221 doi:10.1001/jama.279.3.217.
23. Carson, JL, Terrin, ML, Magaziner, J, et al. Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS). Transfusion 46 (2006), 2192–2206 doi:10.1111/j.1537-2995.2006.01056.x.
24. Hogue, CW Jr, Goodnough, LT, Monk, TG, Perioperative myocardial ischemic episodes are related to hematocrit level in patients undergoing radical prostatectomy. Transfusion 38 (1998), 924–931 doi:10.1046/j.1537-2995.1998.381098440856.x.
25. Nelson, AH, Fleisher, LA, Rosenbaum, SH, Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med 21 (1993), 860–866 doi:10.1097/00003246-199306000-00013.
26. Grover, M, Talwalkar, S, Casbard, A, et al. Silent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty. Vox Sang 90 (2006), 105–112 doi:10.1111/j.1423-0410.2006.00730.x.
27. Carson, JL, Terrin, ML, Barton, FB, et al. A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion 38 (1998), 522–529 doi:10.1046/j.1537-2995.1998.38698326331.x.
28. Carson, JL, Duff, A, Berlin, JA, et al. Perioperative blood transfusion and postoperative mortality. J Am Med Assoc 279 (1998), 199–205 doi:10.1001/jama.279.3.199.
29. Foss, NB, Kristensen, MT, Jensen, PS, et al. The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery. Transfusion 49 (2009), 227–234 doi:10.1111/j.1537-2995.2008.01967.x.
30. Hébert, PC, Wells, G, Blajchman, MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340 (1999), 409–417 doi:10.1056/NEJM199902113400601.
31. Goodnough, LT, Monk, TG, Andriole, GL, Erythropoietin therapy. N Engl J Med 336 (1997), 933–938 doi:10.1056/NEJM199703273361307.
32. Mercuriali, F, Inghilleri, G, Management of preoperative anaemia. Br J Anaesth 81:Suppl. 1 (1998), 56–61.
33. Circular of Information for the Use of Human Blood and Blood Components, 2000, American Association of Blood Banks, Bethesda, MD.
34. Goodnough, LT, Shander, A, Spivak, JL, et al. Detection, evaluation, and management of anemia in the elective surgical patient. Anesth Analg 101 (2005), 1858–1861 doi:10.1213/01.ANE.0000184124.29397.EB.
35. Goodnough, LT, Maniatis, A, Earnshaw, P, Management of preoperative anaemia in patients undergoing elective surgery. ISBT Sci Ser 5 (2010), 120–124 doi:10.1111/j.1751-2824.2010.01368.x.
36. Goodnough, LT, Nemeth, E, Ganz, T, Detection, evaluation, and management of iron-restricted erythropoiesis. Blood, 2010 Sept. 8 [Epub ahead of print].
37. Atkins, D, Best, D, Briss, PA, et al. Grading quality of evidence and strength of recommendations. Br Med J, 328, 2004, 1490 doi:10.1136/bmj.328.7454.1490.
38. Guyatt, GH, Cook, DJ, Jaeschke, R, et al. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008), 123–131 doi:10.1378/chest.08-0654.
39. Mercuriali, F, Zanella, A, Barosi, G, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 33 (1993), 55–60 doi:10.1046/j.1537-2995.1993.33193142311.x.
40. Mast, AE, Blinder, MA, Gronowski, AM, et al. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 44 (1998), 45–51.
41. Andrews, CM, Lane, DW, Bradley, JG, Iron pre-load for major joint replacement. Transfus Med 7 (1997), 281–286 doi:10.1046/j.1365-3148.1997.d01-42.x.
42. Cuenca, J, Garcia-Erce, JA, Martinez, F, et al. Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement. Int J Surg 5 (2007), 89–94 doi:10.1016/j.ijsu.2006.02.003.
43. Lidder, PG, Sanders, G, Whitehead, E, et al. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery—a prospective, randomised, controlled trial. Ann R Coll Surg Engl 89 (2007), 418–421 doi:10.1308/003588407X183364.
44. Okuyama, M, Ikeda, K, Shibata, T, et al. Preoperative iron supplementation and intraoperative transfusion during colorectal cancer surgery. Surg Today 35 (2005), 36–40 doi:10.1007/s00595-004-2888-0.
45. Mundy, GM, Birtwistle, SJ, Power, RA, The effect of iron supplementation on the level of haemoglobin after lower limb arthroplasty. J Bone Joint Surg Br 87 (2005), 213–217.
46. Sutton, PM, Cresswell, T, Livesey, JP, et al. Treatment of anaemia after joint replacement. A double-blind, randomised, controlled trial of ferrous sulphate versus placebo. J Bone Joint Surg Br 86 (2004), 31–33.
47. Weatherall, M, Maling, TJ, Oral iron therapy for anaemia after orthopaedic surgery: randomized clinical trial. ANZ J Surg 74 (2004), 1049–1051 doi:10.1111/j.1445-1433.2004.03265.x.
48. Zauber, NP, Zauber, AG, Gordon, FJ, et al. Iron supplementation after femoral head replacement for patients with normal iron stores. J Am Med Assoc 267 (1992), 525–527 doi:10.1001/jama.267.4.525.
49. Parker, MJ, Iron supplementation for anemia after hip fracture surgery: a randomized trial of 300 patients. J Bone Joint Surg Am 92 (2010), 265–269 doi:10.2106/JBJS.I.00883.
50. Cuenca, J, Garcia-Erce, JA, Munoz, M, et al. Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: a pilot study. Transfusion 44 (2004), 1447–1452 doi:10.1111/j.1537-2995.2004.04088.x.
51. Cuenca, J, Garcia-Erce, JA, Martinez, AA, et al. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data. Arch Orthop Trauma Surg 125 (2005), 342–347 doi:10.1007/s00402-005-0809-3.
52. Theusinger, OM, Leyvraz, PF, Schanz, U, et al. Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: efficacy and limits: a prospective study. Anesthesiology 107 (2007), 923–927 doi:10.1097/01.anes.0000291441.10704.82.
53. Beris, P, Munoz, M, Garcia-Erce, JA, et al. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 100 (2008), 599–604 doi:10.1093/bja/aen054.
54. Besarab, A, Bolton, WK, Browne, JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998), 584–590 doi:10.1056/NEJM199808273390903.
55. Drueke, TB, Locatelli, F, Clyne, N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006), 2071–2084 doi:10.1056/NEJMoa062276.
56. Singh, AK, Szczech, L, Tang, KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006), 2085–2098 doi:10.1056/NEJMoa065485.
57. Pfeffer, MA, Burdmann, EA, Chen, CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (2009), 2019–2032 doi:10.1056/NEJMoa0907845.
58. Palmer, SC, Navaneethan, SD, Craig, JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153 (2010), 23–33.
59. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50 (2007), 471–530 doi:10.1053/j.ajkd.2007.06.008.
60. Locatelli, F, Nissenson, AR, Barrett, BJ, et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 74 (2008), 1237–1240 doi:10.1038/ki.2008.299.
61. Locatelli, F, Covic, A, Eckardt, KU, et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 24 (2009), 348–354 doi:10.1093/ndt/gfn653.
62. Henke, M, Laszig, R, Rube, C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003), 1255–1260 doi:10.1016/S0140-6736(03)14567-9.
63. Leyland-Jones, B, Semiglazov, V, Pawlicki, M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005), 5960–5972 doi:10.1200/JCO.2005.06.150.
64. Bokemeyer, C, Aapro, MS, Courdi, A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43 (2007), 258–270 doi:10.1016/j.ejca.2006.10.014.
65. Aapro, MS, Link, H, September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13:Suppl. 3 (2008), 33–36 doi:10.1634/theoncologist.13-S3-33.
66. Rizzo, JD, Somerfield, MR, Hagerty, KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 111 (2008), 25–41 doi:10.1182/blood-2007-08-109488.
67. Bennett, CL, Silver, SM, Djulbegovic, B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J Am Med Assoc 299 (2008), 914–924 doi:10.1001/jama.299.8.914.
68. Bohlius, J, Schmidlin, K, Brillant, C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373 (2009), 1532–1542 doi:10.1016/S0140-6736(09)60502-X.
69. Tonelli, M, Hemmelgarn, B, Reiman, T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. Can Med Assoc J 180 (2009), E62–E71.
70. Adamson, JW, Erythropoietic-stimulating agents: the cancer progression controversy and collateral damage to the blood supply. Transfusion 49 (2009), 824–826 doi:10.1111/j.1537-2995.2009.02165.x.
71. Stowell, CP, Chandler, H, Jove, M, et al. An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. Orthopedics 22 (1999), s105–s112.
72. DA Fergusson, B Hutton, A Maniatis, et al., Use of recombinant human erythropoietin in orthopaedic surgery: a systematic review, (submitted for publication).
73. Canadian Orthopedic Perioperative Erythropoietin Study Group, Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 341 (1993), 1227–1232.
74. de Andrade, JR, Jove, M, Landon, G, et al. Baseline hemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients. Am J Orthop 25 (1996), 533–542.
75. Faris, PM, Ritter, MA, Abels, RI, The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The American Erythropoietin Study Group. J Bone Joint Surg Am 78 (1996), 62–72.
76. Feagan, BG, Wong, CJ, Kirkley, A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 133 (2000), 845–854.
77. Green, D, Lawler, M, Rosen, M, et al. Recombinant human erythropoietin: effect on the functional performance of anemic orthopedic patients. Arch Phys Med Rehabil 77 (1996), 242–246 doi:10.1016/S0003-9993(96)90105-7.
78. Olijhoek, G, Megens, JG, Musto, P, et al. Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion 41 (2001), 957–963 doi:10.1046/j.1537-2995.2001.41070957.x.
79. Weber, EW, Slappendel, R, Hemon, Y, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 22 (2005), 249–257 doi:10.1017/S0265021505000426.
80. Aksoy, MC, Tokgozoglu, AM, Erythropoietin for autologous blood donation in total hip arthroplasty patients. Arch Orthop Trauma Surg 121 (2001), 162–165 doi:10.1007/s004020000197.
81. Avall, A, Hyllner, M, Bengtson, JP, et al. Recombinant human erythropoietin in preoperative autologous blood donation did not influence the haemoglobin recovery after surgery. Acta Anaesthesiol Scand 47 (2003), 687–692 doi:10.1034/j.1399-6576.2003.00130.x.
82. Baudoux, E, Autologous blood donation plus epoetin alfa in nonanemic orthopedic surgery patients. Semin Hematol 33 (1996), 31–32.
83. Beris, P, Mermillod, B, Levy, G, et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study. Vox Sang 65 (1993), 212–218 doi:10.1111/j.1423-0410.1993.tb02152.x.
84. Bezwada, HP, Nazarian, DG, Henry, DH, Booth, RE Jr., Preoperative use of recombinant human erythropoietin before total joint arthroplasty. J Bone Joint Surg Am 85-A (2003), 1795–1800.
85. Biesma, DH, Kraaijenhagen, RJ, Marx, JJ, van de Wiel, A, The efficacy of subcutaneous recombinant human erythropoietin in the correction of phlebotomy-induced anemia in autologous blood donors. Transfusion 33 (1993), 825–829 doi:10.1046/j.1537-2995.1993.331094054619.x.
86. Biesma, DH, Marx, JJ, Kraaijenhagen, RJ, et al. Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin. Lancet 344 (1994), 367–370 doi:10.1016/S0140-6736(94)91401-X.
87. Biesma, DH, Van de Wiel, A, Beguin, Y, et al. Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy. Eur J Clin Invest 24 (1994), 426–432 doi:10.1111/j.1365-2362.1994.tb02187.x.
88. Cazenave, JP, Irrmann, C, Waller, C, et al. Epoetin alfa facilitates presurgical autologous blood donation in non-anaemic patients scheduled for orthopaedic or cardiovascular surgery. Eur J Anaesthesiol 14 (1997), 432–442 doi:10.1097/00003643-199707000-00015.
89. de Pree, C, Mermillod, B, Hoffmeyer, P, Beris, P, Recombinant human erythropoietin as adjuvant treatment for autologous blood donation in elective surgery with large blood needs (> or =5 units): a randomized study. Transfusion 37 (1997), 708–714 doi:10.1046/j.1537-2995.1997.37797369446.x.
90. Goodnough, LT, Price, TH, Rudnick, S, Soegiarso, RW, Preoperative red cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion 32 (1992), 441–445 doi:10.1046/j.1537-2995.1992.32592327718.x.
91. Goodnough, LT, Rudnick, S, Price, TH, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 321 (1989), 1163–1168 doi:10.1056/NEJM198910263211705.
92. Hasegawa, Y, Takamatsu, J, Iwase, T, et al. Effects of recombinant human erythropoietin on thrombosis and fibrinolysis in autologous transfusion for hip surgery. Arch Orthop Trauma Surg 119 (1999), 384–387 doi:10.1007/s004020050434.
93. Mercuriali, F, Inghilleri, G, Biffi, E, et al. Epoetin alfa in low hematocrit patients to facilitate autologous blood donation in total hip replacement: a randomized, double-blind, placebo-controlled, dose-ranging study. Acta Haematol 100 (1998), 69–76 doi:10.1159/000040868.
94. Price, TH, Goodnough, LT, Vogler, WR, et al. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion 36 (1996), 29–36 doi:10.1046/j.1537-2995.1996.36196190512.x.
95. Sans, T, Bofil, C, Joven, J, et al. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery. Transfusion 36 (1996), 822–826 doi:10.1046/j.1537-2995.1996.36996420762.x.
96. Schlaeppi, B, Gunter, P, Nydegger, UE, Enhancing the efficacy of preoperative autologous blood donation by erythropoietin. Transfus Sci 15 (1994), 171–177 doi:10.1016/0955-3886(94)90092-2.
97. Shapiro, GS, Boachie-Adjei, O, Dhawlikar, SH, Maier, LS, The use of epoetin alfa in complex spine deformity surgery. Spine 27 (2002), 2067–2071 doi:10.1097/00007632-200209150-00019.
98. Tryba, M, Epoetin alfa plus autologous blood donation and normovolemic hemodilution in patients scheduled for orthopedic or vascular surgery. Semin Hematol 33 (1996), 34–36 discussion 7–8.
99. Tryba, M, Epoetin alfa plus autologous blood donation in patients with a low hematocrit scheduled to undergo orthopedic surgery. Semin Hematol 33 (1996), 22–24 discussion 5–6.
100. von Bormann, B, Weidler, B, Friedrich, M, von Andrian-Werburg, H, Recombinant erythropoietin in autologous blood donation. Anaesthesist 40 (1991), 386–390.
101. Deutsch, A, Spaulding, J, Marcus, RE, Preoperative epoetin alfa vs autologous blood donation in primary total knee arthroplasty. J Arthroplasty 21 (2006), 628–635 doi:10.1016/j.arth.2005.12.002.
102. Gombotz, H, Gries, M, Sipurzynski, S, et al. Preoperative treatment with recombinant human erythropoietin or predeposit of autologous blood in women undergoing primary hip replacement. Acta Anaesthesiol Scand 44 (2000), 737–742 doi:10.1034/j.1399-6576.2000.440613.x.
103. Hardwick, ME, Morris, BM, Colwell, CW Jr., Two-dose epoetin alfa reduces blood transfusions compared with autologous donation. Clin Orthop Relat Res 423 (2004), 240–244 doi:10.1097/01.blo.0000130206.58617.9e.
104. Keating, EM, Callaghan, JJ, Ranawat, AS, et al. A randomized, parallel-group, open-label trial of recombinant human erythropoietin vs preoperative autologous donation in primary total joint arthroplasty: effect on postoperative vigor and handgrip strength. J Arthroplasty 22 (2007), 325–333 doi:10.1016/j.arth.2006.11.002.
105. Rosencher, N, Poisson, D, Albi, A, et al. Two injections of erythropoietin correct moderate anemia in most patients awaiting orthopedic surgery. Can J Anaesth 52 (2005), 160–165 doi:10.1007/BF03027722.
106. Goldberg, MA, McCutchen, JW, Jove, M, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 25 (1996), 544–552.
107. Mercuriali, F, Inghilleri, G, Biffi, E, et al. Comparison between intravenous and subcutaneous recombinant human erythropoietin (epoetin alfa) administration in presurgical autologous blood donation in anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Vox Sang 72 (1997), 93–100 doi:10.1046/j.1423-0410.1997.7220093.x.
108. Tsutsui, H, Sugioka, Y, Takaku, F, et al. A double-blind dose ranging study of weekly subcutaneous administration of rHuEPO (KRN5702) on post-phlebotomy anemia of patients scheduled for predeposit autologous blood transfusion (multicenter late PhII study). Nippon Seikeigeka Gakkai Zasshi 67 (1993), 919–934.
109. Moonen, AF, Thomassen, BJ, Knoors, NT, et al. Pre-operative injections of epoetin-alpha versus post-operative retransfusion of autologous shed blood in total hip and knee replacement: a prospective randomised clinical trial. J Bone Joint Surg Br 90 (2008), 1079–1083 doi:10.1302/0301-620X.90B8.20595.
110. Goodnough, LT, Skikne, B, Brugnara, C, Erythropoietin, iron, and erythropoiesis. Blood 96 (2000), 823–833.